Masanori Abe

Summary

Affiliation: Nihon University
Country: Japan

Publications

  1. Hatanaka Y, Higuchi T, Akiya Y, Horikami T, Tei R, Furukawa T, et al. Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Hemodialysis. Blood Purif. 2019;47 Suppl 2:38-44 pubmed publisher
    ..0001). The prevalence rates of carnitine deficiency and carnitine insufficiency were high in patients on dialysis. The serum carnitine reduction rate was greater with HDF than with HD. ..
  2. Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Hanafusa N, et al. Predictors of outcomes in patients on peritoneal dialysis: A 2-year nationwide cohort study. Sci Rep. 2019;9:3967 pubmed publisher
    ..509 (95% confidence interval 1.029-2.189, P = 0.036) in the diabetes group. Diabetes, older age, longer duration of dialysis, cardiovascular comorbidity, and inflammation were predictors of mortality in patients on PD. ..
  3. Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci Rep. 2019;9:3320 pubmed publisher
    ..Thus, GA ≥ 20.0% appears to be associated with a decrease in survival in diabetic patients on PD. There were no associations between HbA1c levels and 2-year mortality in PD patients. ..
  4. Maruyama T, Maruyama N, Higuchi T, Nagura C, Takashima H, Kitai M, et al. Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial. Eur J Clin Nutr. 2019;73:293-301 pubmed publisher
    ..92 % (95% CI 1.28-4.61; P = 0.0007). L-carnitine supplementation is useful in patients who develop carnitine deficiency on hemodialysis because it maintains physical function and LBM. ..
  5. Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Rate of the "burnt-out diabetes" phenomenon in patients on peritoneal dialysis. Diabetes Res Clin Pract. 2018;143:254-262 pubmed publisher
    ..9%). Although the "burnt-out diabetes" phenomenon was present in 17.7% of patients with diabetes on PD based on HbA1c, the rate was significantly decreased to 10.9% when taking GA into account. ..
  6. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res. 2011;34:935-41 pubmed publisher
  7. Abe M, Oikawa O, Okada K, Soma M. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. J Renin Angiotensin Aldosterone Syst. 2015;16:159-64 pubmed publisher
    ..Olmesartan may have the unique effect of increasing urinary ACE2 levels. However, whether this contributes to olmesartan's renoprotective effect must be examined further. ..
  8. Higuchi T, Abe M, Yamazaki T, Mizuno M, Okawa E, Ando H, et al. Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial. Nutrients. 2014;6:5992-6004 pubmed publisher
    ..L-carnitine supplementation significantly reduced baPWV in HD patients. L-carnitine may be a novel therapeutic strategy for preventing the progression of atherosclerotic cardiovascular disease. ..
  9. Maruyama T, Fukuda N, Matsumoto T, Kano K, Endo M, Kazama M, et al. Systematic implantation of dedifferentiated fat cells ameliorated monoclonal antibody 1-22-3-induced glomerulonephritis by immunosuppression with increases in TNF-stimulated gene 6. Stem Cell Res Ther. 2015;6:80 pubmed publisher
    ..Thus DFAT cells will be suitable cell source for the treatment of immunological progressive renal diseases. ..

More Information

Publications22

  1. Kobayashi H, Abe M, Okada K, Tei R, Maruyama N, Kikuchi F, et al. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Nutrients. 2015;7:3783-95 pubmed publisher
    ..Zinc supplementation reduces ERI in patients undergoing HD and may be a novel therapeutic strategy for patients with renal anemia and low serum zinc levels. ..
  2. Higuchi T, Abe M, Mizuno M, Yamazaki T, Suzuki H, Moriuchi M, et al. Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis. Sleep Med. 2015;16:941-8 pubmed publisher
    ..Further studies are needed to identify detailed risk factors and the pathophysiological role of oxidative stress in RLS. ..
  3. Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M. Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis. Clin Drug Investig. 2017;37:95-102 pubmed publisher
    ..If adverse effects are carefully monitored and the administered dosage prudently determined, pregabalin can be an effective treatment for peripheral neuropathic pain in patients undergoing hemodialysis. UMIN000023117. ..
  4. Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, et al. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. Diabetes Res Clin Pract. 2016;116:244-52 pubmed publisher
    ..Saxagliptin (2.5mg/day) was effective and well tolerated when used as monotherapy or combined with other antidiabetic drugs in Japanese hemodialysis patients with type 2 diabetes. UMIN000018445. ..
  5. Furukawa T, Okada K, Abe M, Tei R, Oikawa O, Maruyama N, et al. Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. Int J Mol Sci. 2015;16:30181-9 pubmed publisher
    ..However, the results suggest that subcutaneous administration of DA or CERA once every four weeks to predialysis patients has similar effects on achievement of target Hb levels. ..
  6. Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K. Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis. Int J Mol Sci. 2016;17: pubmed publisher
    ..Although GA might underestimate glycemic status, it provided a significantly better measure for estimating glycemic control than HbA1c, even in PD patients. ..
  7. Higuchi T, Abe M, Yamazaki T, Okawa E, Ando H, Hotta S, et al. Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial. Am J Kidney Dis. 2016;67:260-70 pubmed publisher
    ..Levocarnitine therapy is useful for hemodialysis patients with carnitine deficiency; these patients may benefit from such therapy, with amelioration of cardiac function and reduction of left ventricular mass index. ..
  8. request reprint
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18:1018-28 pubmed
    ..0006, R(2)= 0.53). Rosuvastatin administration reduced albuminuria, oxidative stress, and serum cystatin C levels, independent of blood pressure and lipid levels. ..
  9. Abe M, Okada K, Maruyama N, Matsumoto S, Fuke Y, Fujita T, et al. A case of femoral hemorrhage in a patient with microscopic polyangiitis with low levels of myeloperoxidase-antineutrophil cytoplasmic autoantibody. Clin Exp Nephrol. 2011;15:414-418 pubmed publisher
    ..Thereafter, her renal function improved, and she was discharged. To our knowledge, this is the first report of a case of microscopic polyangiitis accompanied by femoral hemorrhage. ..
  10. Arimura T, Abe M, Shiga H, Katayama H, Kaizu K, Oda S. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. J Artif Organs. 2017;20:244-251 pubmed publisher
    ..This large-scale cohort study showed the clinical status of BPT in Japan. Further investigations are required to clarify the efficacy of BPT for critically ill patients. ..
  11. Abe M, Hamano T, Hoshino J, Wada A, Inaba M, Nakai S, et al. Is there a "burnt-out diabetes" phenomenon in patients on hemodialysis?. Diabetes Res Clin Pract. 2017;130:211-220 pubmed publisher
    ..Although the "burnt-out diabetes" phenomenon might be present in 20.7% of patients with diabetes on HD in terms of HbA1c, the rate was significantly decreased to 5.4% in terms of GA. UMIN000018641. ..
  12. request reprint
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K, Soma M. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes. Int J Artif Organs. 2011;34:16-25 pubmed
    ..This study aimed to explore the relationship between recombinant human erythropoietin (EPO) responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients...
  13. Abe M, Maruyama N, Suzuki H, Okada K, Soma M. International normalized ratio decreases after hemodialysis treatment in patients treated with warfarin. J Cardiovasc Pharmacol. 2012;60:502-7 pubmed publisher
    ..The INR depletion was therefore dependent on circulating plasma volumes and serum albumin concentrations. Caution should be taken for those HD patients who have absolute indications of anticoagulation therapy with warfarin. ..